ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1924

Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials

Dania Kaur1, Fizza Zulfiqar2, Akshee Batra3 and Abhinav Vyas4, 1North Alabama Medical Center, Muscle Shoals, AL, 2Trinity Health Oakland/Wayne State University, Pontiac, MI, 3University of Miami, Miami, FL, 4Vanderbilt University Medical Center, Nahville, TN

Meeting: ACR Convergence 2024

Keywords: gender, Psoriatic arthritis, race/ethnicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Healthcare Disparities in Rheumatology Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: To develop effective novel treatment strategies for psoriatic arthritis that cater to patients from diverse backgrounds, it is crucial that all racial groups, without exception, have equal opportunities to participate in clinical trials.

Methods: Using ClinicalTrials.gov, a web-based resource that registers all studies meeting the definition of a clinical trial according to the International Committee on Medical Journal Editors, we identified all phase 1 to phase 4 psoriatic arthritis clinical trials. We manually abstracted data on the racial distribution of enrolled participants, sex distribution, trial phase, location, and year of trial reporting. Additionally, we conducted subgroup analyses of racial distribution based on trial phase and location and evaluated trends in racial disparity within clinical trial enrollment over the years.

Results: We identified 84 clinical trials related to Psoriatic arthritis, of which 91.6% were done in Europe or the United States. Most of these were phase 3 clinical trials (60.7%). The racial distribution of enrolled participants was publicly available in 51(60.7%)  clinical trials. The race distribution of enrolled subjects was reported in 50% of Phase 1, 70.6% in Phase 2, 60.9% in Phase 3 and 60% in Phase 4. The race distribution among 15266 study participants in 51 clinical trials was: 85.1% Whites (12997), 1.25 % Blacks (182), 9.2% Asians (1399), 2% other races (306), and 1.6% (246) subjects with unreported race. The same race distribution trend was observed across all subgroups of clinical trials based on phase. The sex distribution, as seen throughout the trials, was 51.9% in males(13998) and 48.1% in females(12959).

Conclusion: Our research has shown that only 60.7% of psoriatic arthritis studies had racial distribution published. We noted a decreased representation of blacks, whereas a higher representation of Asians. Strategies to implement equitable representation in clinical trials in psoriatic arthritis are needed.


Disclosures: D. Kaur: None; F. Zulfiqar: None; A. Batra: None; A. Vyas: None.

To cite this abstract in AMA style:

Kaur D, Zulfiqar F, Batra A, Vyas A. Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/racial-and-gender-disparities-in-psoriatic-arthritis-clinical-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/racial-and-gender-disparities-in-psoriatic-arthritis-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology